Trial Profile

An Exploratory phase II Study of Eribrin rechallenge after short term therapy of 5-FU for HER2 negative, advanced/recurrent breast cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eribulin (Primary) ; Gimeracil/oteracil/tegafur
Indications Advanced breast cancer
Focus Therapeutic Use

Most Recent Events

01 Oct 2021 Results published in the Anticancer Research
09 Nov 2020 Status changed from recruiting to active, no longer recruiting.
03 Oct 2020 Results presented at the Official 12th European Breast Cancer Conference

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com